Structural and Functional Basis of CXCL12 (stromal Cell-derived Factor-1α) Binding to Heparin
James W. Murphy,Yoonsang Cho,Aristidis Sachpatzidis,Chengpeng Fan,Michael E. Hodsdon,Elias Lolis
DOI: https://doi.org/10.1074/jbc.m608796200
IF: 5.485
2007-01-01
Journal of Biological Chemistry
Abstract:CXCL12 (SDF-1α) and CXCR4 are critical for embryonic development and cellular migration in adults. These proteins are involved in HIV-1 infection, cancer metastasis, and WHIM disease. Sequestration and presentation of CXCL12 to CXCR4 by glycosaminoglycans (GAGs) is proposed to be important for receptor activation. Mutagenesis has identified CXCL12 residues that bind to heparin. However, the molecular details of this interaction have not yet been determined. Here we demonstrate that soluble heparin and heparan sulfate negatively affect CXCL12-mediated in vitro chemotaxis. We also show that a cluster of basic residues in the dimer interface is required for chemotaxis and is a target for inhibition by heparin. We present structural evidence for binding of an unsaturated heparin disaccharide to CXCL12 attained through solution NMR spectroscopy and x-ray crystallography. Increasing concentrations of the disaccharide altered the two-dimensional 1H-15N-HSQC spectra of CXCL12, which identified two clusters of residues. One cluster corresponds to β-strands in the dimer interface. The second includes the amino-terminal loop and the α-helix. In the x-ray structure two unsaturated disaccharides are present. One is in the dimer interface with direct contacts between residues His25, Lys27, and Arg41 of CXCL12 and the heparin disaccharide. The second disaccharide contacts Ala20, Arg21, Asn30, and Lys64. This is the first x-ray structure of a CXC class chemokine in complex with glycosaminoglycans. Based on the observation of two heparin binding sites, we propose a mechanism in which GAGs bind around CXCL12 dimers as they sequester and present CXCL12 to CXCR4. CXCL12 (SDF-1α) and CXCR4 are critical for embryonic development and cellular migration in adults. These proteins are involved in HIV-1 infection, cancer metastasis, and WHIM disease. Sequestration and presentation of CXCL12 to CXCR4 by glycosaminoglycans (GAGs) is proposed to be important for receptor activation. Mutagenesis has identified CXCL12 residues that bind to heparin. However, the molecular details of this interaction have not yet been determined. Here we demonstrate that soluble heparin and heparan sulfate negatively affect CXCL12-mediated in vitro chemotaxis. We also show that a cluster of basic residues in the dimer interface is required for chemotaxis and is a target for inhibition by heparin. We present structural evidence for binding of an unsaturated heparin disaccharide to CXCL12 attained through solution NMR spectroscopy and x-ray crystallography. Increasing concentrations of the disaccharide altered the two-dimensional 1H-15N-HSQC spectra of CXCL12, which identified two clusters of residues. One cluster corresponds to β-strands in the dimer interface. The second includes the amino-terminal loop and the α-helix. In the x-ray structure two unsaturated disaccharides are present. One is in the dimer interface with direct contacts between residues His25, Lys27, and Arg41 of CXCL12 and the heparin disaccharide. The second disaccharide contacts Ala20, Arg21, Asn30, and Lys64. This is the first x-ray structure of a CXC class chemokine in complex with glycosaminoglycans. Based on the observation of two heparin binding sites, we propose a mechanism in which GAGs bind around CXCL12 dimers as they sequester and present CXCL12 to CXCR4. Chemokines are a superfamily of 8-11-kDa secreted chemotactic cytokines, which are modulated by glycosaminoglycans (GAGs), 3The abbreviations used are: GAG, glycosaminoglycan; HEK-293, human embryonic kidney 293; HSQC, heteronuclear single quantum coherence. 3The abbreviations used are: GAG, glycosaminoglycan; HEK-293, human embryonic kidney 293; HSQC, heteronuclear single quantum coherence. activate chemokine receptors, and direct cellular migration (1Fernandez E.J. Lolis E. Annu. Rev. Pharmacol. Toxicol. 2002; 42: 469-499Crossref PubMed Scopus (494) Google Scholar). The 43 known human chemokines are divided into two major and two minor families. All have a three-dimensional structure composed of a three-stranded β-sheet followed by an α-helix, which is stabilized by conserved cysteine residues forming typically two disulfide bonds (Fig. 1A) (2Lapidot T. Petit I. Exp. Hematol. 2002; 30: 973-981Abstract Full Text Full Text PDF PubMed Scopus (691) Google Scholar). The chemokine CXCL12 (CXCL12) is the sole physiological agonist for CXCR4 (3Bleul C.C. Farzan M. Choe H. Parolin C. Clark-Lewis I. Sodroski J. Springer T.A. Nature. 1996; 382: 829-833Crossref PubMed Scopus (1743) Google Scholar). CXCL12 has been observed as a dimer in several crystal structures (4Dealwis C. Fernandez E.J. Thompson D.A. Simon R.J. Siani M.A. Lolis E. Proc. Natl. Acad. Sci. U. S. A. 1998; 95: 6941-6946Crossref PubMed Scopus (150) Google Scholar, 5Ohnishi Y. Senda T. Nandhagopal N. Sugimoto K. Shioda T. Nagal Y. Mitsui Y. J. Interferon Cytokine Res. 2000; 20: 691-700Crossref PubMed Scopus (45) Google Scholar). However, it has been reported as both a monomer and as a dimer in solution (6Crump M.P. Gong J.H. Loetscher P. Rajarathnam K. Amara A. Arenzana-Seisdedos F. Virelizier J.L. Baggiolini M. Sykes B.D. Clark-Lewis I. EMBO J. 1997; 16: 6996-7007Crossref PubMed Scopus (625) Google Scholar, 7Holmes W.D. Consler T.G. Dallas W.S. Rocque W.J. Willard D.H. Protein Expr. Purif. 2001; 21: 367-377Crossref PubMed Scopus (37) Google Scholar). The oligomeric state is modulated by pH, concentration, and the presence of divalent cations and heparin (8Veldkamp C.T. Peterson F.C. Pelzek A.J. Volkman B.F. Protein Sci. 2005; 14: 1071-1081Crossref PubMed Scopus (143) Google Scholar). The CXCL12/CXCR4 signaling axis is critically involved in a wide variety of physiological functions. These include margination of neutrophils into the site of infection (9White F.A. Bhangoo S.K. Miller R.J. Nat. Rev. Drug Discov. 2005; 4: 834-844Crossref PubMed Scopus (215) Google Scholar, 10Kucia M. Jankowski K. Reca R. Wysoczynski M. Bandura L. Allendorf D.J. Zhang J. Ratajczak J. Ratajczak M.Z. J. Mol. Histol. 2004; 35: 233-245Crossref PubMed Scopus (589) Google Scholar), embryonic development (11Nagasawa T. Tachibana K. Kishimoto T. Semin. Immunol. 1998; 10: 179-185Crossref PubMed Scopus (204) Google Scholar), mobilization and directed migration of stem cells (12Kucia M. Reca R. Miekus K. Wanzeck J. Wojakowski W. Janowska-Wieczorek A. Ratajczak J. Ratajczak M.Z. Stem Cells (Durham). 2005; 23: 879-894Crossref PubMed Scopus (659) Google Scholar, 13Kucia M. Ratajczak J. Ratajczak M.Z. Biol. Cell. 2005; 97: 133-146Crossref PubMed Scopus (140) Google Scholar), and neurological function (14Bajetto A. Bonavia R. Barbero S. Florio T. Schettini G. Front. Neuroendocrinol. 2001; 22: 147-184Crossref PubMed Scopus (326) Google Scholar). CXCR4 is involved in HIV-1 infection and HIV-associated dementia (15Zhou N. Luo Z. Luo J. Liu D. Hall J.W. Pomerantz R.J. Huang Z. J. Biol. Chem. 2001; 276: 42826-42833Abstract Full Text Full Text PDF PubMed Scopus (118) Google Scholar, 16Kaul M. Lipton S.A. Curr. HIV Res. 2006; 4: 307-318Crossref PubMed Scopus (138) Google Scholar), is implicated in cancer metastasis (17Muller A. Homey B. Soto H. Ge N. Catron D. Buchanan M.E. McClanahan T. Murphy E. Yuan W. Wagner S.N. Barrera J.L. Mohar A. Verastegui E. Zlotnik A. Nature. 2001; 410: 50-56Crossref PubMed Scopus (4387) Google Scholar, 18Luker K.E. Luker G.D. Cancer Lett. 2006; 238: 30-41Crossref PubMed Scopus (229) Google Scholar, 19Epstein R.J. Nat. Rev. Cancer. 2004; 4: 901-909Crossref PubMed Scopus (116) Google Scholar), and genetic mutants are responsible for WHIM disease (20Diaz G.A. Gulino A.V. Curr. Allergy Asthma Rep. 2005; 5: 350-355Crossref PubMed Scopus (46) Google Scholar). There is mounting evidence that glycosaminoglycans modulate the activity of chemokines via direct interactions (21Handel T.M. Johnson Z. Crown S.E. Lau E.K. Proudfoot A.E. Annu. Rev. Biochem. 2005; 74: 385-410Crossref PubMed Scopus (422) Google Scholar). Although the complete functionality of these interactions is not yet completely understood, it is believed that GAGs and proteoglycans sequester chemokines (22Lau E.K. Allen S. Hsu A.R. Handel T.M. Adv. Protein Chem. 2004; 68: 351-391Crossref PubMed Scopus (55) Google Scholar). This sequestering increases dimerization and local concentrations, in turn leading to the formation of a chemokine gradient (21Handel T.M. Johnson Z. Crown S.E. Lau E.K. Proudfoot A.E. Annu. Rev. Biochem. 2005; 74: 385-410Crossref PubMed Scopus (422) Google Scholar, 22Lau E.K. Allen S. Hsu A.R. Handel T.M. Adv. Protein Chem. 2004; 68: 351-391Crossref PubMed Scopus (55) Google Scholar, 23Johnson Z. Proudfoot A.E. Handel T.M. Cytokine Growth Factor Rev. 2005; 16: 625-636Crossref PubMed Scopus (196) Google Scholar). In addition, heparan sulfate presents CXCL12 to CXCR4-expressing leukocytes (22Lau E.K. Allen S. Hsu A.R. Handel T.M. Adv. Protein Chem. 2004; 68: 351-391Crossref PubMed Scopus (55) Google Scholar). Another important functional aspect of heparin binding to CXCL12 is protection from proteolysis by dipeptidyl peptidase IV (CD26), which removes the NH2-terminal two residues thus inactivating CXCL12 (24Sadir R. Imberty A. Baleux F. Lortat-Jacob H. J. Biol. Chem. 2004; 279: 43854-43860Abstract Full Text Full Text PDF PubMed Scopus (169) Google Scholar). CXCL12 was originally shown to possess affinity for heparin and heparan sulfate by binding to heparin affinity resin (25Bleul C.C. Fuhlbrigge R.C. Casasnovas J.M. Aiuti A. Springer T.A. J. Exp. Med. 1996; 184: 1101-1109Crossref PubMed Scopus (1261) Google Scholar). It was proposed that positively charged CXCL12 and other chemokines interact with negatively charged GAGs through non-specific electrostatic interactions. However, this interaction was subsequently shown to be specific (26Amara A. Lorthioir O. Valenzuela A. Magerus A. Thelen M. Montes M. Virelizier J.L. Delepierre M. Baleux F. Lortat-Jacob H. Arenzana-Seisdedos F. J. Biol. Chem. 1999; 274: 23916-23925Abstract Full Text Full Text PDF PubMed Scopus (282) Google Scholar). CXCL12 bound independently of its receptor to CXCR4-negative cells through interaction with cell surface glycosaminoglycans. Amara et al. (26Amara A. Lorthioir O. Valenzuela A. Magerus A. Thelen M. Montes M. Virelizier J.L. Delepierre M. Baleux F. Lortat-Jacob H. Arenzana-Seisdedos F. J. Biol. Chem. 1999; 274: 23916-23925Abstract Full Text Full Text PDF PubMed Scopus (282) Google Scholar) proceeded to use site-directed mutagenesis of CXCL12 to identify a BBXB motif on the first β-strand (Lys24, His25, and Lys27) that was critical for this in vitro interaction. This triple mutant retained its in vitro biological activity of stimulating intracellular calcium mobilization. However, the mutated CXCL12 had significantly decreased affinity for heparin (26Amara A. Lorthioir O. Valenzuela A. Magerus A. Thelen M. Montes M. Virelizier J.L. Delepierre M. Baleux F. Lortat-Jacob H. Arenzana-Seisdedos F. J. Biol. Chem. 1999; 274: 23916-23925Abstract Full Text Full Text PDF PubMed Scopus (282) Google Scholar). Interestingly, mutants of the CC chemokines CCL2 (MCP-1), CCL4 (MIP-1β), and CCL5 (RANTES) devoid of heparin binding retain in vitro chemotactic activity but lose in vivo activity (27Proudfoot A.E. Handel T.M. Johnson Z. Lau E.K. LiWang P. Clark-Lewis I. Borlat F. Wells T.N. Kosco-Vilbois M.H. Proc. Natl. Acad. Sci. U. S. A. 2003; 100: 1885-1890Crossref PubMed Scopus (627) Google Scholar). A model of the CXCL12-heparin complex was based on the mutagenesis studies (28Sadir R. Baleux F. Grosdidier A. Imberty A. Lortat-Jacob H. J. Biol. Chem. 2001; 276: 8288-8296Abstract Full Text Full Text PDF PubMed Scopus (192) Google Scholar). Sadir et al. (28Sadir R. Baleux F. Grosdidier A. Imberty A. Lortat-Jacob H. J. Biol. Chem. 2001; 276: 8288-8296Abstract Full Text Full Text PDF PubMed Scopus (192) Google Scholar) calculated an electrostatic potential map of CXCL12 and docked a heparin tetradecasaccharide into the positively charged groove. Energy minimization produced a structure in which heparin was modeled to bind quite well in the putative binding site between the subunits of the CXCL12 dimer. In the proposed model, heparin interacted primarily with the basic residues Lys1, Lys24, His25, Lys27, Arg41, and Lys43 and secondarily with Asn46 and Gln48. We determined that heparan sulfate as well as high and low molecular weight heparins have a concentration-dependent negative effect on CXCL12 driven chemotaxis of CXCR4+ CEM-CCRF cells. Our mutational data revealed a cluster of negatively charged residues involved in both chemotaxis and heparin binding. To elucidate the interactions between the proposed residues and heparin, we used NMR spectroscopy to monitor backbone chemical shift perturbations of CXCL12 during a titration with a heparin disaccharide. By using the fully sulfated, unsaturated disaccharide (heparin disaccharide I-S) derived from a fully sulfated heparin (Fig. 1B), we were able to use the minimum size that contains the basic structural elements required for CXCL12 binding. One chemical difference to be noted between this disaccharide and a typical heparin oligomer is the presence of a double bond between C4 and C5 of the uronic acid, making the disaccharide non-physiological. However, the relative positions of the sulfate moieties should remain unchanged. Therefore we used this disaccharide as a model for CXCL12-heparin interactions. The addition of the disaccharide affected two clusters of amino acids in a dose-dependent manner in NMR spectroscopy experiments. We then used x-ray crystallography to define the exact binding position of the disaccharides. The results from NMR spectroscopy combined with the crystal structure of CXCL12 in complex with the disaccharides define specific molecular interactions between CXCL12 and heparin. Our results not only support previous findings that heparin binds to basic residues in the dimer interface (26Amara A. Lorthioir O. Valenzuela A. Magerus A. Thelen M. Montes M. Virelizier J.L. Delepierre M. Baleux F. Lortat-Jacob H. Arenzana-Seisdedos F. J. Biol. Chem. 1999; 274: 23916-23925Abstract Full Text Full Text PDF PubMed Scopus (282) Google Scholar, 28Sadir R. Baleux F. Grosdidier A. Imberty A. Lortat-Jacob H. J. Biol. Chem. 2001; 276: 8288-8296Abstract Full Text Full Text PDF PubMed Scopus (192) Google Scholar) but also identify an additional binding site. Reagents—Luria-Bertani medium, ampicillin, isopropyl 1-thio-β-d-galactopyranoside, Triton X-100, and dithiothreitol were purchased from American Bioanalytical (Natick, MA). 15N-ammonium chloride (98% 15N), heparin disaccharide I-S (containing an unsaturated hexauronate), oxidized and reduced glutathione, protease inhibitor mixture, ammonium sulfate, Trizma base (Tris base), and deuterium oxide were purchased from Sigma. CXCL12 Expression, Folding, and Purification—The gene encoding human CXCL12 was cloned into the NdeI and XhoI restriction sites of the pET-22b expression vector (Novagen®). The resulting plasmid was transformed into Escherichia coli BL21(DE3). 1.5 liters of Luria-Bertani media containing 100 μg/ml ampicillin were inoculated and grown to A600 of 0.6 and then induced with 1.0 mm isopropyl 1-thio-β-d-galactopyranoside. Induced cultures were grown for an additional4hat 37 °C and harvested by centrifugation for 10 min at 5000 × g. Cells were resuspended in 1× phosphate-buffered saline (pH 7.4) with 1% Triton X-100, lysed using a French Press and centrifuged for 20 min at 30,000 × g. CXCL12 was found exclusively in inclusion bodies. The inclusion bodies were washed three times in wash buffer A (100 mm Tris·HCl, pH 8.0, 5 mm EDTA, 5 mm dithiothreitol, 2 m urea, 2% Triton X-100) and once with wash buffer B (100 mm Tris·HCl, pH 8.0, 5 mm EDTA, 5mm dithiothreitol). Washed inclusion bodies were solubilized in 6 m guanidine HCl and diluted 1:100 into a refolding buffer (100 mm Tris·HCl, pH 8.0, 5 mm EDTA, 0.2 mm oxidized glutathione, 1 mm reduced glutathione) and stirred at 4 °C overnight. Precipitated material was removed by filtration. Refolded protein was bound to a SP-Sepharose column and eluted with a NaCl gradient. Fractions containing CXCL12 were pooled and were further purified by reverse phase-HPLC. The peak containing CXCL12 was concentrated and lyophilized. CXCL12 was resuspended in sterile ddH2O (pH 7.0) with 0.1 mm NaN3 and protease inhibitor mixture prior to use. Protein concentration was determined by direct amino acid analysis at the W. M. Keck facility (Yale University). 15N-Labeled CXCL12—Isotopically labeled 15N-CXCL12 was produced similar to native protein with the exception of the substitution of LB medium with M9 minimal media containing 1.0 g/liters of 15NH4Cl (98% 15N). Expression and Purification of Mutant CXCL12—For the chemotaxis assays, wild-type and mutant CXCL12 were expressed in HEK-293 cells to ensure proper folding using a mammalian expression vector containing a secretion signal sequence and an Fc tag at the carboxyl terminus of CXCL12 (kind gift of Timothy Springer of Harvard University). Mutagenesis of the plasmid was accomplished using the QuikChange and Multi-site QuikChange procedures (Stratagene). The proper sequence of all mutated plasmids was verified by DNA sequencing at the W. M. Keck facility (Yale University). HEK-293 cells were transformed at partial confluence by the calcium phosphate transfection method. After 24 h, the growth media containing secreted CXCL12-Fc was collected and treated with iodoacetamide to prevent aggregation. CXCL12-Fc was purified using protein A-Sepharose affinity chromatography. Cell Culture and Chemotaxis Assays—The CCRF-CEM acute lymphoblastic leukemia cell line (29Foley G.E. Lazarus H. Farber S. Uzman B.G. Boone B.A. Mc-Carthy R.E. Cancer. 1965; 18: 522-529Crossref PubMed Scopus (985) Google Scholar) was obtained from the American Type Culture Collection (CCL-119) and maintained as recommended by the ATCC. Chemotaxis assays were performed as previously described (30Sachpatzidis A. Benton B.K. Manfredi J.P. Wang H. Hamilton A. Dohlman H.G. Lolis E. J. Biol. Chem. 2003; 278: 896-907Abstract Full Text Full Text PDF PubMed Scopus (111) Google Scholar). Briefly, semi-confluent cells were harvested and resuspended to ∼1 × 107 cells/ml. 100-μl Aliquots of cells were then placed in the upper chamber of a transwell (Corning-Costar®) with 5 μm pore size. Varying concentrations of CXCL12, heparin, and heparan sulfate are in the lower chamber. Following a 2-h incubation at 37 °C, cells which migrated to the lower chamber were counted with an electronic particle counter (Coulter®). NMR Spectroscopy—Samples for NMR spectroscopy contained 2 mm 15N-CXCL12, 10 mm HEPES, pH 7.4, and 5% D2O with variable concentrations of heparin disaccharide I-S (0-12 mm). Experiments were carried out at 35 °C in a Varian INOVA 600 MHz spectrometer with a 5-mm triple resonance probe equipped with triple-axis (XYZ) pulsed magnetic field gradients. All pulse sequences were taken from the Varian BioPack user library. Spectra were processed and analyzed using the programs nmrPipe (31Delaglio F. Grzesiek S. Vuister G.W. Zhu G. Pfeifer J. Bax A. J. Biomol. NMR. 1995; 6: 277-293Crossref PubMed Scopus (11280) Google Scholar) and Sparky. 4T. D. Goddard and D. G. Kneller, personal communication. Assignment of resonance peaks was done using three-dimensional 15N-TOCSY HSQC and 15N-NOESY HSQC NMR spectra of CXCL12 alone and previously published resonance assignments (33Gozansky E.K. Louis J.M. Caffrey M. Clore G.M. J. Mol. Biol. 2005; 345: 651-658Crossref PubMed Scopus (54) Google Scholar). Crystallography—CXCL12 was concentrated to 12 mg/ml in water. Protein crystals were grown using the hanging drop method in the previously published condition (2 m ammonium sulfate, 0.1 m Tris·HCl, pH 8.5) at 18 °C (4Dealwis C. Fernandez E.J. Thompson D.A. Simon R.J. Siani M.A. Lolis E. Proc. Natl. Acad. Sci. U. S. A. 1998; 95: 6941-6946Crossref PubMed Scopus (150) Google Scholar). The crystals were soaked into 4-μl drops of heparin disaccharide I-S (16 mm) in 20% PEG-8000, 0.1 m Tris·HCl (pH 8.5) and incubated overnight at 18 °C. The crystals were protected in 20% PEG-8000, 0.1 m Tris·HCl (pH 8.5), and 25% glycerol for 1 min and frozen at -180 °C during data collection. Data Collection and Processing—X-ray diffraction data were collected on an R-axis IV detector (Rigaku) at the macromolecular crystallography facility at the Yale University School of Medicine. Data were processed using MOSFLM (34Leslie A.G. Acta Crystallogr. D Biol. Crystallogr. 1999; 55: 1696-1702Crossref PubMed Scopus (485) Google Scholar) and SCALA (35Four Collaborative Computational Project Number Acta Crystallogr. D Biol. Crystallogr. 1994; 50: 760-763Crossref PubMed Scopus (19668) Google Scholar). Phaser (36McCoy A.J. Grosse-Kunstleve R.W. Storoni L.C. Read R.J. Acta Crystallogr. D Biol. Crystallogr. 2005; 61: 458-464Crossref PubMed Scopus (1590) Google Scholar) was used for molecular replacement. The CCP4i software suite (37Potterton E. Briggs P. Turkenburg M. Dodson E. Acta Crystallogr. D Biol. Crystallogr. 2003; 59: 1131-1137Crossref PubMed Scopus (1042) Google Scholar) and the Crystallography and NMR (CNS) (38Brunger A.T. Adams P.D. Clore G.M. DeLano W.L. Gros P. Grosse-Kunstleve R.W. Jiang J.S. Kuszewski J. Nilges M. Pannu N.S. Read R.J. Rice L.M. Simonson T. Warren G.L. Acta Crystallogr. D Biol. Crystallogr. 1998; 54: 905-921Crossref PubMed Scopus (16919) Google Scholar) program suite were used for refinement and structure validation. Initial coordinates and structural libraries of the heparin disaccharide were created using the Dundee PRODRG server (39Schuttelkopf A.W. van Aalten D.M. Acta Crystallogr. D Biol. Crystallogr. 2004; 60: 1355-1363Crossref PubMed Scopus (4063) Google Scholar). Mutagenesis of Wild-type CXCL12-Fc Affects Chemotaxis and Inhibition of Chemotaxis by GAGs—Recombinant, refolded CXCL12 produced in E. coli and Fc-tagged CXCL12 produced in HEK-293 cells had equivalent chemotactic activity (data not shown). A series of mutants of CXCL12 were designed to probe the effect of various surface areas in CXCR4 binding and activation (Fig. 1A). The EC50 values and efficacies of these mutants as compared with the wild-type protein are in Table 1. The chemotactic index is a measure of the chemotactic activity of each protein, defined as the ratio of the number of cells migrated for each protein concentration to the number of cells migrated in response to assay media without chemokine. Efficacy (%) as used in Table 1 is a measure of the maximum activity of each mutant relative to the maximum chemotaxis of the wild type CXCL12.TABLE 1Effect of CXCL12 mutations on chemotaxisMutantEC50aEC50 was defined as the concentration of CXCL12 that gave 50% of the maximum response as determined by a concentration-response curve for each mutant.EfficacybEfficacy was calculated as the ratio of the maximum response of each mutant to the maximum response of wild-type CXCL12 multiplied by 100.nM%Wild-type7.9100R8Q/R12Q960110R8Q490100R12Q3592F13A/F14A2187E15Q/H17N13110T31G/A33G/A35G1881H25N/K27Q/R41Q/R47Q/Q48N4.166a EC50 was defined as the concentration of CXCL12 that gave 50% of the maximum response as determined by a concentration-response curve for each mutant.b Efficacy was calculated as the ratio of the maximum response of each mutant to the maximum response of wild-type CXCL12 multiplied by 100. Open table in a new tab The RFFESH motif (residues 12-17) was shown by others to have a role in receptor binding and activation through the use of chimeric chemokines with CXCL12 sequences, receptor binding assays, and intracellular calcium release upon agonist activation (6Crump M.P. Gong J.H. Loetscher P. Rajarathnam K. Amara A. Arenzana-Seisdedos F. Virelizier J.L. Baggiolini M. Sykes B.D. Clark-Lewis I. EMBO J. 1997; 16: 6996-7007Crossref PubMed Scopus (625) Google Scholar). We further explored this region with the single mutant R12Q and two double mutants, F13A/F14A and E15Q/H17N. Our results show increases in EC50 values ranging from 1.6 to 4.4-fold for the three mutants relative to wild-type CXCL12. Although our results cannot be directly compared with those of Crump et al. (6Crump M.P. Gong J.H. Loetscher P. Rajarathnam K. Amara A. Arenzana-Seisdedos F. Virelizier J.L. Baggiolini M. Sykes B.D. Clark-Lewis I. EMBO J. 1997; 16: 6996-7007Crossref PubMed Scopus (625) Google Scholar) due to differences in assays (chemotaxis versus Ca2+ mobilization), we agree that this region is important for CXCL12 function, with no particular residue making a large contribution relative to others. We were surprised, however, by the effect of Arg8 on the EC50. The maximum activity of three mutants R8Q, R12Q, and R8Q/R12Q is similar to wild type, but these mutants have correspondingly 60, 4, and 120 times higher EC50 values than the wild type. The positive charge of Arg8 is critical for activating CXCR4-mediated chemotaxis. A series of other mutants were designed to address the role of positively charged surface areas identified originally in the CXCL12 crystal structure (4Dealwis C. Fernandez E.J. Thompson D.A. Simon R.J. Siani M.A. Lolis E. Proc. Natl. Acad. Sci. U. S. A. 1998; 95: 6941-6946Crossref PubMed Scopus (150) Google Scholar). One of these, a quintuple mutant H25N/K27Q/R41Q/R47Q/Q48N that removed the charges showed a 35% reduction in efficacy with respect to wild type but a similar EC50 suggesting that the loss of a large surface area of positive potential has a moderate effect on receptor activation. Alternatively, because this mutant showed a clear resistance to heparin inhibition (see below), its reduced activity may be due to a lack of interaction with native GAGs essential for a maximum chemotactic effect. A triple mutant comprising residues T31V/A33G/A35G showed a small reduction of EC50 and efficacy suggesting a possible role of these residues in CXCL12-CXCR4 interaction. Effect of GAGs on CXCL12-mediated Chemotaxis—As shown in Fig. 2, A and B, both heparan sulfate and high and low molecular weight heparin caused a clear reduction of the chemotactic activity of CXCL12 in all CXCL12 and GAG concentrations tested. The effect was significant at 10 or 100 μg/ml of GAG for both 10 and 100 nm CXCL12. These data are in agreement with previous observations on the negative regulatory effects of soluble GAGs on in vitro binding of CXCL12 to various cell lines (40Mbemba E. Benjouad A. Saffar L. Gattegno L. Virology. 1999; 265: 354-364Crossref PubMed Scopus (21) Google Scholar, 41Mbemba E. Gluckman J.C. Gattegno L. Glycobiology. 2000; 10: 21-29Crossref PubMed Google Scholar) and are consistent with a sequestration mechanism that prevents the interaction of the chemokine with the cell surface. It is important to clarify that these data do not preclude the positive regulatory role of native GAGs on CXCL12 activity and proper presentation to its receptor CXCR4. In fact, treatment of cells with enzymes known to degrade GAGs (heparitinases) induces a significant reduction of CXCL12 binding to cells (40Mbemba E. Benjouad A. Saffar L. Gattegno L. Virology. 1999; 265: 354-364Crossref PubMed Scopus (21) Google Scholar, 41Mbemba E. Gluckman J.C. Gattegno L. Glycobiology. 2000; 10: 21-29Crossref PubMed Google Scholar) indicating an important role of native membrane-bound GAGs in binding CXCL12 and increasing its local availability for interaction with CXCR4. It is also noteworthy that soluble GAGs have similar inhibitory effects on the activities of most other chemokines tested up to now (21Handel T.M. Johnson Z. Crown S.E. Lau E.K. Proudfoot A.E. Annu. Rev. Biochem. 2005; 74: 385-410Crossref PubMed Scopus (422) Google Scholar, 22Lau E.K. Allen S. Hsu A.R. Handel T.M. Adv. Protein Chem. 2004; 68: 351-391Crossref PubMed Scopus (55) Google Scholar, 23Johnson Z. Proudfoot A.E. Handel T.M. Cytokine Growth Factor Rev. 2005; 16: 625-636Crossref PubMed Scopus (196) Google Scholar) with the exception of the positive effect of heparan sulfate on neutrophil responses to CXCL8 (interleukin-8) (42Webb L.M. Ehrengruber M.U. Clark-Lewis I. Baggiolini M. Rot A. Proc. Natl. Acad. Sci. U. S. A. 1993; 90: 7158-7162Crossref PubMed Scopus (408) Google Scholar). It is likely that the soluble heparins that inhibit chemotaxis either do not form a receptor-activating complex with the chemokine or compete with the membrane-bound glycosaminoglycans on the cell that would result in an activated complex. Effect of Heparin on the Activity of CXCL12 Mutants—Most CXCL12 mutants tested showed significant heparin-induced inhibition of their chemotactic activity (Fig. 3). The F13A/F14A and E15Q/H17N double mutants and the T31V/A33G/A35G triple mutant showed a level of inhibition comparable with that of the wild-type protein indicating that the GAG-chemokine interaction was not significantly modified in these mutants. On the contrary, the H25N/K27Q/R41Q/R47Q/Q48N quintuple mutant showed a clear resistance to inhibition by heparin indicating that the GAG-CXCL12 interaction has been significantly disrupted. Four positive charges are neutralized in this mutant and the data support the suggestion that some or all of these residues, His25, Lys27, Arg41, Arg47 (and Gln48), are somehow involved in GAG binding. This is in agreement with previous mutagenesis studies (26Amara A. Lorthioir O. Valenzuela A. Magerus A. Thelen M. Montes M. Virelizier J.L. Delepierre M. Baleux F. Lortat-Jacob H. Arenzana-Seisdedos F. J. Biol. Chem. 1999; 274: 23916-23925Abstract Full Text Full Text PDF PubMed Scopus (282) Google Scholar). The most unexpected observation from this series of experiments came from the effect of heparin on the R8Q and R12Q single mutants. In both of these cases, the mutants showed a remarkable hypersensitivity to heparin with more than 80% of the activity lost upon binding a GAG vers